{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T08:15:02Z","timestamp":1788077702850,"version":"build-2784847793"},"reference-count":30,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:p>Background: Methamphetamine (MA) use induces oxidative stress and metabolic dysregulation. Objectives: This study is to compare and explore the association between oxidative stress markers and cardio metabolic risk factors in order to elucidate potential mechanisms linking MA use with metabolic and cardiovascular complications. Methods: A comparative cross-sectional study was conducted and a total of 70 males aged 18 years and above were enrolled from Mamajee Welfare Trust: 35 healthy controls (Group A) and 35 MA users (Group B) confirmed via drug panel testing. Sociodemographic characteristics, substance use patterns, lifestyle behaviors and anthropometric indices were recorded through structured questionnaires. Fasting blood samples were analyzed for lipid profile, fasting plasma glucose, Troponin-I and antioxidant enzyme activities using standardized assays. Data analysis was performed using statistical packages for social sciences (SPSS) software (version 20). Results: MA users reported significantly higher smoking, alcohol intake and physical inactivity. Body mass index (BMI) and systolic blood pressure were also significantly elevated (p&lt;0.01). MA users exhibited pronounced dyslipidemia with increased lipid variables. Antioxidant enzyme activity was significantly lower in MA users, with higher catalase (5.31 \u00b1 0.15 vs. 4.89 \u00b1 0.32 ng\/mL; p=0.047) and superoxide dismutase (SOD) levels (127 \u00b1 43.1 vs. 109 \u00b1 23.4 pg\/mL; p=0.003) in healthy controls vs. MA users, respectively. In methamphetamine users, catalase correlated positively with BMI, cholesterol, triglycerides and low-density lipoprotein (LDL). While SOD in this group showed a significant positive association with blood pressure, lipid markers and very low density lipoprotein (VLDL), with a near-significant trend for Troponin-I. A significant interrelationship between catalase and SOD (r=0.381, p=0.003) in MA users was also observed. In multivariable analysis, MA use and antioxidant enzyme levels (catalase, SOD) were independently associated with BMI, blood pressure and lipid abnormalities. Conclusion: MA use is associated with considerable cardiometabolic disturbances and compromised antioxidant defenses, highlighting the need for early screening and preventive interventions.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.9.255.1","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T07:44:16Z","timestamp":1782632656000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the impact of antioxidant enzymes on cardiometabolic health markers among methamphetamine users compared with healthy participants"],"prefix":"10.36721","author":[{"given":"Irfanullah","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,6,14]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Akhigbe R and Ajayi A (2021). The impact of reactive oxygen species in the development of cardiometabolic disorders: A review. Lipids in Healt. Dis., 20(1): 23-27.","DOI":"10.1186\/s12944-021-01435-7"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Ajayi AI and Okoro IO (2024). Effects of methamphetamine exposure on lipid profile and cardiovascular risk in Wistar rats. J. Applied Sci Environment Managem., 28(10): 3347-3351.","DOI":"10.4314\/jasem.v28i10.49"},{"key":"ref2","unstructured":"Algahtani T, Le Ruez T, Strang J, Morgan D, Smith M and Copeland CS (2025). High BMI is a specific risk factor for drug related mortality in patients receiving methadone: A case control study. Addiction, 13(1): 1-6."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Asia TLRHS (2023). Escape from quicksand: Illicit drug use among youth in southeast Asia. Lancet Reg Healt Southeast Asia, 10(1): 100175.","DOI":"10.1016\/j.lansea.2023.100175"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Chen L, Ru Q, Xiong Q, Yang J, Xu G and Wu Y (2022). Potential effects of Nrf2 in exercise intervention of neurotoxicity caused by methamphetamine oxidative stress. Oxidativ Med Cellular longevity. 2022(1): 4445734.","DOI":"10.1155\/2022\/4445734"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Hajam YA, Rani R, Ganie SY, Sheikh TA, Javaid D, Qadri SS, Pramodh S, Alsulimani A, Alkhanani MF, Harakeh S and Hussain A (2022). Oxidative stress in human pathology and aging: Molecular mechanisms and perspectives. Cells, 11(3): 552-559.","DOI":"10.3390\/cells11030552"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Hassan K, Mohydin B, Fawwad A, Waris N, Iqbal S and Jawaid M (2019). Predicting the risk of atherosclerotic cardiovascular disease (ASCVD) in Pakistani population. Clin Epidemiol Global Healt, 7(2): 184-187.","DOI":"10.1016\/j.cegh.2018.04.002"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Hemphill K, Tierney S, Tirschwell D and Davis AP (2024). A review of methamphetamine uses and stroke in the young. Front in Neurolog, 15(1): 139767.","DOI":"10.3389\/fneur.2024.1397677"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Huang MC, Yang SY, Lin SK, Chen KY, Chen YY, Kuo CJ and Hung YN (2016). Risk of cardiovascular diseases and stroke events in methamphetamine users: A 10-year follow-up study. J Clinic Psychiatr, 77(10): 11856.","DOI":"10.4088\/JCP.15m09872"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Jaafari-Sheybani F, Hoseini SE, Mehrabani D, Derakhshanfar A and Karimi-Busheri F (2021). Histological changes in adipose tissue: An alarm when methamphetamine is targeted for weight loss purposes. World J Plastic Surg., 10(1): 53-59.","DOI":"10.29252\/wjps.10.1.53"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Jan SUK, Alam H and Khan A (2021). An analysis of risk factors associated with methamphetamine\/ICE use in Khyber. Global Sociological Rev, 6(1): 111-118.","DOI":"10.31703\/gsr.2021(VI-I).15"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Jayanthi S, McCoy MT and Cadet JL (2021). Epigenetic regulatory dynamics in models of methamphetamine-use disorder. Genes, 12(10): 1614-1619.","DOI":"10.3390\/genes12101614"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Kolluru GK, Glawe JD, Pardue S, Kasabali A, Alam S, Rajendran S, Cannon AL, Abdullah CS, Traylor JG, Shackelford RE and Woolard MD (2022). Methamphetamine causes cardiovascular dysfunction via cystathionine gamma lyase and hydrogen sulfide depletion. Redox Biol., 57(1): 102480.","DOI":"10.1016\/j.redox.2022.102480"},{"key":"ref13","unstructured":"Koohsar JS, Faeghi F, Rafaiee R, Sarvandani MN, Masjoodi S and Moghaddam HK (2022). Metabolite alternations in the dopamine circuit associated with methamphetamine-related psychotic symptoms: A proton magnetic resonance spectroscopy study. Iranian J Psychiat., 17(1): 91-99."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Lei XG, Zhu JH, Cheng WH, Bao Y, Ho YS, Reddi AR, Holmgren A and Arner ES (2016). Paradoxical roles of antioxidant enzymes: Basic mechanisms and health implications. Physiologic Rev., 96(1): 307-364.","DOI":"10.1152\/physrev.00010.2014"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Li Y, Simmler LD, Van Zessen R, Flakowski J, Wan JX, Deng F, Li YL, Nautiyal KM, Pascoli V and Luscher C (2021). Synaptic mechanism underlying serotonin modulation of transition to cocaine addiction. Science, 373(6560): 1252-1256.","DOI":"10.1126\/science.abi9086"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Mbugua S, Mecha E, Kirira P, Njoroge M, Malala B, Gitaka J, Makokha F and Mwenda C (2022). Association between metabolic syndrome and substance dependence: A cross-sectional study in Kenya. European J Med Healt Sci., 4(3): 170-174.","DOI":"10.24018\/ejmed.2022.4.3.1030"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"McDonnell-Dowling KP and Kelly J (2017). The role of oxidative stress in methamphetamine-induced toxicity and sources of variation in the design of animal studies. Current Neuropharmacol., 15(2): 300-314.","DOI":"10.2174\/1570159X14666160428110329"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Moszczynska A (2021). Current and emerging treatments for methamphetamine use disorder. Current Neuropharmacol., 19(12): 2077-91.","DOI":"10.2174\/1570159X19666210803091637"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Obolski J, Sawyer DB, Song SJ and Afari ME (2022). Cardiovascular disease associated with methamphetamine use: A review. Heart Failure Rev., 27(6): 2059-65.","DOI":"10.1007\/s10741-022-10261-7"},{"key":"ref20","unstructured":"Panchal N (2020). Sexual orientation, body mass index and methamphetamine use among Chicago youth (Doctoral dissertation, Walden University)."},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Pauly RC, Bhimani RV, Li JX, Blough BE, Landavazo A and Park J (2023). Distinct effects of methamphetamine isomers on limbic norepinephrine and dopamine transmission in the rat brain. ACS chemic neurosci., 14(8): 1399-411.","DOI":"10.1021\/acschemneuro.2c00689"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Pergolizzi Jr JV, Raffa RB, Rosenblatt MH (2020). Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. J Clinic Pharmacy Therapeut., 45(5): 892-903.","DOI":"10.1111\/jcpt.13114"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Pisarski K (2021). A narrative review of the recent \u2018ice\u2019 epidemic: An Australian perspective. Substan abuse, 15(1): 11782218211010502.","DOI":"10.1177\/11782218211010502"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Rajput VD, Harish, Singh RK, Verma KK, Sharma L and Quiroz-Figueroa FR (2021). Recent developments in enzymatic antioxidant defence mechanism in plants with special reference to abiotic stress. Biology, 10(4): 267-271.","DOI":"10.3390\/biology10040267"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Schwarzbach V, Lenk K and Laufs U (2020). Methamphetamine-related cardiovascular diseases. ESC Heart Failu., 7(2): 407-414.","DOI":"10.1002\/ehf2.12572"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Stacescu S, Hancu G, Podar D, Todea S and Tero-Vescan A (2019). A historical overview upon the use of amphetamine derivatives in the treatment of obesity. J Pharmaceutic Care, 28(1): 72-79.","DOI":"10.18502\/jpc.v7i3.2355"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Tobolski J, Sawyer DB, Song SJ and Afari ME (2022). Cardio vascular disease associated with methamphetamine use: A review. Heart Failure Rev., 27(6): 2059-65.","DOI":"10.1007\/s10741-022-10261-7"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Viola TW, Orso R, Florian LF, Garcia MG, Gomes MG, Mardini EM and Grassi-Oliveira R (2023). Effects of substance use disorder on oxidative and antioxidative stress markers: A systematic review and meta-analysis. Addiction Biol., 28(1): e13254.","DOI":"10.1111\/adb.13254"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Wahab S, Chun Keat T, Azmi AD, Mahadevan R, Muhamed Ramli ER and Kian Boon L (2021). Risk of depression among MMT patients: Does coping strategies and perceived social support play a role? Substan abuse, 15(1): 11782218211049407.","DOI":"10.1177\/11782218211049407"}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T07:53:59Z","timestamp":1788076439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pjps.pk\/single-article?id=7860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,14]]},"references-count":30,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.9.255.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,14]]}}}